Pharming Group N.V. confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.

For media and investors only

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September:

Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2024.

Pharming Group N.V. confirms it will report its preliminary (unaudited) second quarter and first half 2024 financial results, for the period ended June 30, on Thursday, August 1, 2024.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of June:

Pharming Group N.V. announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Pharming Group N.V. announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of May: